Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 3

Incidence of Endophthalmitis Following the Intravitreal Injections

İntravitreal Enjeksiyon Sonrası Endoftalmi Görülme İnsidansı

Pages
199–205
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall incidence of endophthalmitis was 0.10% per injection (4 of 3925 injections) and 0.38% per eye (4 of 1054 eyes).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To report the incidence of acute postoperative endophthalmitis secondary to intravitreal injections.
📊
Key Findings & Data:Materials and Methods: A retrospective review of patients who were followed by a single retinal specialist and treated with intravitreal injections between January 2004 to May 2013.
💡
Conclusion & Impact:The overall incidence of endophthalmitis was 0.10% per injection (4 of 3925 injections) and 0.38% per eye (4 of 1054 eyes).
🔬Design:Review & Systematic Survey
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To report the incidence of acute postoperative endophthalmitis secondary to intravitreal injections. Materials and Methods: A retrospective review of patients who were followed by a single retinal specialist and treated with intravitreal injections between January 2004 to May 2013. Patients who were referred from other clinics as endophthalmitis were not included. Results: During the study interval, 3925 intravitreal injections were performed in 1054 eyes of 788 patients. The mean number of injection per eye was 3.72±3.43 . The mean age of the participants was 67.04±13.55 (Range, 5-94 years). 371 participants (47.1%) were female and 417 participants (52.9%) were male. Mean follow-up was 31.92±22.91 month (Range, 1-144 months). Four endophthalmitis cases were noted over the last 9 years. The overall incidence of endophthalmitis was 0.10% per injection (4 of 3925 injections) and 0.38% per eye (4 of 1054 eyes). Conclusions: Endophthalmitis is a rare but serious complication that may occur after any intravitreal injection. To reduce its incidence, clinics should evaluate their own data and elucidate the risk factors

Özet

Amaç: İntravitreal enjeksiyon tedavisi sonrasında görülen endoftalmi sıklığını belirlemek. Gereç ve Yöntem: Ocak 2004-Mayıs 2013 tarihleri arasında bir retina uzmanının takibinde olan ve intravitreal enjeksiyon yapılan olguların kayıtları geriye dönük olarak incelendi. Başka bir tedavi merkezinden enjeksiyon sonrası endoftalmi tanısı ile sevk edilen olgular, çalışmaya dahil edilmedi.Sonuçlar: Çalışmaya 788 hastanın 1054 gözü dahil edilirken, çalışma süresi boyunca toplam 3925 intravitreal enjeksiyon uygulandı. Bir göz başına ortama intravitreal enjeksiyon sayısı 3.72±3.43 olarak hesaplandı. Hastaların ortalama yaşı 67.04±13.55 (5-94 yaş) ve kadın/erkek oranı 371/417 (%47.1/%52.9) idi. Ortalama takip süresi 31.92±22.91 aydı (1-144 ay arası). Geriye dönük yaklaşık 10 yıllık sürede toplam dört endoftalmi olgusu tespit edildi. Enjeksiyon başına endoftalmi insidansı %0.10 (4/3925) bulunurken, tedavi edilen göz başına endoftalmi sıklığı %0.38 (4/1054) olarak tespit edildi.Tartışma: Endoftalmi, intravitreal enjeksiyon sonrasında nadir görülen, fakat morbiditesi yüksek bir komplikasyondur. Bu komplikasyonun sıklığını en alt düzeye indirmek için uygulayıcı kliniklerin kendi verilerini ve risk faktörlerini değerlendirmesi yararlı bir yaklaşım olacaktır

🔖

Cite This Article

KARABAĞ, R. Y., DORA, G. Ç., PARLAK, M., SAATÇİ, A. O. (2015). Incidence of Endophthalmitis Following the Intravitreal Injections. Retina-Vitreus, Cilt: 23 - Sayı: 3, 199–205. https://ajindex.com/articles/308009

References (14)

  1. Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676-98.
  2. Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications af- ter anti-vascular endothelial growth factor therapy in medicare pa- tients with age-related macular degeneration. Am J Ophthalmol 2011;152:266-72.
  3. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intra- ocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-4.
  4. Saeed MU, Prasad S. Management of cataract caused by inadvertent capsule penetration during intravitreal injection of ranibizumab. J Ca- taract Refract Surg 2009;35:1857-9.
  5. Fileta JB, Scott IU, Flynn HW Jr. Meta-analysis of infectious en- dophthalmitis after intravitreal injection of anti-vascular endothe- lial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2014;45:143-9.
  6. Kernt M, Kampik A. Endophthalmitis: pathogenesis, clinical presenta- tion, management, and perspectives. Clin Ophthalmol 2010;4:121-35.
  7. Minassian DC, Reidy A, Lightstone A, et al. Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol 2011;95:1433-6.
  8. Englander M, Chen TC, Paschalis EI, et al. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment in- dications and postinjection endophthalmitis rates. Br J Ophthalmol 2013;97:460-5.
  9. Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, et al. Endoph- thalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Re- tina 2014;34:943-50.
  10. Alkın Z, Kapran Z, Sayın N, ve ark. İntravitreal enjeksiyonların göze ait ve sistemik komplikasyonları. Ret-Vit 2010;18:210-5.
  11. Rosenfeld PJ, Brown DM, Heier JS, et al (MARINA Study Group). Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 2006;355:1419-31.
  12. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve- month safety of intravitreal injections of bevacizumab (Avastin): re- sults of the Pan-American Collaborative Retina Study Group (PACO- RES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7.
  13. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for ne- ovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606-11.
  14. Brown DM, Miche